Phase I-II Study of Pegylated Liposomal Doxorubicin Combined With Weekly Paclitaxel as First-Line Treatment in Patients With Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Phase I-II Study of Pegylated Liposomal Doxorubicin Combined With Weekly Paclitaxel as First-Line Treatment in Patients With Metastatic Breast Cancer

Published:2006-06 Issue:3 Volume:29 Page:267-275
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Bourgeois Hugues,Ferru Aurélie,Lortholary Alain,Delozier Thierry,Boisdron-Celle Michèle,Abadie-Lacourtoisie Sophie,Joly Florence,Chieze Stéphanie,Chabrun Virginie,Gamelin Erick,Tourani Jean-Marc

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference26 articles.

1. Cancer statistics.;Jemal;CA Cancer J Clin,2004

2. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.;O'shaughnessy;J Clin Oncol,2002

3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.;Slamon;N Engl J Med,2001

4. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).;Sledge;J Clin Oncol,2003

5. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group.;Chan;J Clin Oncol,1999

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin;Molecular Pharmaceutics;2016-12-16

2. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer;Biomaterials;2014-07

3. WP 631 and Epo B synergize in SKOV-3 human ovarian cancer cells;Environmental Toxicology and Pharmacology;2014-01

4. Reversion of pH-Induced Physiological Drug Resistance: A Novel Function of Copolymeric Nanoparticles;PLoS ONE;2011-09-26

5. Antitumor activity of IHL-305, a novel pegylated liposome containing irinotecan, in human xenograft models;Oncology Reports;2011-09-20